Autologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency)

N/A

Report date: 2024/01/18 20:05:22

Base Information

Drug NameAutologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency)
Drug Alias NameCLIC-2201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBritish Columbia Cancer Agency
China Registration ClassN/A

Develop Information

Active CompaniesBritish Columbia Cancer Agency
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A